{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/ALLR",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Allarity Therapeutics, Inc. (NASDAQ: ALLR) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Allarity Therapeutics, Inc., listed on NASDAQ under ticker ALLR, ISIN US0167445008; its LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 49 filings across 38 filing days in the window 2025-11-08 to 2026-11-08, with a median gap of 6 days between filing days. The latest filing is dated 2026-11-02, a corporate_news filing, 6 days before the record date of 2026-11-08. On NASDAQ the median filings count is 52, the median cadence gap is 6.0 days and the median latency is 5.0 days across 4,359 issuers. In sector 2834 Pharmaceutical Preparations the median filings count is 63.0, the median cadence gap is 6.0 days and the median latency is 4.0 days across 526 issuers. The issuer's 49 filings are below the NASDAQ median and below the sector median.\n\n## Auditor\n\nThe auditor of record is Wolf & Company P.C., located in Boston, Massachusetts. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record names 2 research houses on the issuer's investor-relations page: Ascendiant Capital Markets, LLC and Zacks Investment Research, Inc.\n\n## Open research\n\nThe record holds 4 openly published research notes: Zacks Small-Cap Research on 2023-12-07, Ladenburg Thalmann & Co. on 2023-12-07, Ladenburg Thalmann & Co. on 2023-03-28, and Zacks Investment Research on 2022-09-13.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n13 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001860657.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/ALLR (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://allarity.com/analysts/ (coverage)\n- https://allarity.com/wp-content/uploads/2023/12/Zacks_SCR_Research_12072023_ALLR_Vandermosten_Note.pdf (open research)\n- https://allarity.com/wp-content/uploads/2023/12/ALLR-note-12.7.2023.pdf (open research)\n- https://allarity.com/wp-content/uploads/2023/03/ALLR-note-3.28.2023-Ladenburg.pdf (open research)\n- https://allarity.com/wp-content/uploads/2024/01/Zacks_SCR_Research_09132022_ALLR_Vandermosten.pdf (open research)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/ALLR (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm",
    "state": "sourced",
    "value": "Wolf & Company P.C."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm",
    "state": "sourced",
    "value": "392"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm",
    "state": "sourced",
    "value": "Boston, Massachusetts"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/ALLR",
  "coverage": {
   "count": 2,
   "houses": [
    {
     "analyst": "Edward Woo, CFA",
     "house": "Ascendiant Capital Markets, LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://allarity.com/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "John D. Vandermosten, CFA",
     "house": "Zacks Investment Research, Inc.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://allarity.com/analysts/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://allarity.com/analysts/",
     "result": "read: 2 of 2 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "ad_hoc": 2,
    "agm_egm": 4,
    "corporate_news": 15,
    "director_change": 2,
    "directors_dealings": 8,
    "prospectus": 6,
    "regulatory_filing": 6,
    "results": 6
   },
   "cadence_median_gap_days": 6,
   "filing_days": 38,
   "filings": 49,
   "latency_days": 6,
   "latest": [
    {
     "category": "8-K",
     "date": "2026-11-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1860657/000121390026114682/ea0310390-8k_allarity.htm",
     "title": "8-K — CURRENT REPORT (items 1.01,8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "424B5",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1860657/000121390026114390/ea0310280-424b5_allarity.htm",
     "title": "424B5 — PROSPECTUS SUPPLEMENT",
     "type": "prospectus"
    },
    {
     "category": "8-K",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1860657/000121390026114380/ea0310280-8k_allarity.htm",
     "title": "8-K — CURRENT REPORT (items 1.02)",
     "type": "ad_hoc"
    },
    {
     "category": "4",
     "date": "2026-10-09",
     "source": "https://www.sec.gov/Archives/edgar/data/1860657/000121390026108573/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-10-01",
     "source": "https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/ea0307298-8k_allarity.htm",
     "title": "8-K — CURRENT REPORT (items 8.01,9.01)",
     "type": "corporate_news"
    }
   ],
   "latest_filing_date": "2026-11-02",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ALLR",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US0167445008"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001860657.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001860657.json",
    "state": "sourced",
    "value": "Allarity Therapeutics, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001860657.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001860657.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "ALLR"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:f4e1550ef44764328189ac2f4b004f10639f9d5d0f5ee0730a9ddf58181ccc27",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [
    {
     "date": "2023-12-07",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Small-Cap Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://allarity.com/wp-content/uploads/2023/12/Zacks_SCR_Research_12072023_ALLR_Vandermosten_Note.pdf",
     "state": "sourced",
     "title": "ALLR: Stenoparib Clinical Update"
    },
    {
     "date": "2023-12-07",
     "kind": "independent",
     "publisher": "Ladenburg Thalmann & Co.",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://allarity.com/wp-content/uploads/2023/12/ALLR-note-12.7.2023.pdf",
     "state": "sourced",
     "title": "Estimate Changes"
    },
    {
     "date": "2023-03-28",
     "kind": "independent",
     "publisher": "Ladenburg Thalmann & Co.",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://allarity.com/wp-content/uploads/2023/03/ALLR-note-3.28.2023-Ladenburg.pdf",
     "state": "sourced",
     "title": "Allarity Therapeutics Inc."
    },
    {
     "date": "2022-09-13",
     "kind": "issuer-sponsored",
     "publisher": "Zacks Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://allarity.com/wp-content/uploads/2024/01/Zacks_SCR_Research_09132022_ALLR_Vandermosten.pdf",
     "state": "sourced",
     "title": "Initiating Coverage"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/ALLR",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:f4e1550ef44764328189ac2f4b004f10639f9d5d0f5ee0730a9ddf58181ccc27",
 "path": "/us/NASDAQ/ALLR",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Allarity Therapeutics, Inc., listed on NASDAQ under ticker ALLR, ISIN US0167445008; its LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 49 filings across 38 filing days in the window 2025-11-08 to 2026-11-08, with a median gap of 6 days between filing days. The latest filing is dated 2026-11-02, a corporate_news filing, 6 days before the record date of 2026-11-08. On NASDAQ the median filings count is 52, the median cadence gap is 6.0 days and the median latency is 5.0 days across 4,359 issuers. In sector 2834 Pharmaceutical Preparations the median filings count is 63.0, the median cadence gap is 6.0 days and the median latency is 4.0 days across 526 issuers. The issuer's 49 filings are below the NASDAQ median and below the sector median.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Wolf & Company P.C., located in Boston, Massachusetts. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record names 2 research houses on the issuer's investor-relations page: Ascendiant Capital Markets, LLC and Zacks Investment Research, Inc.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 4 openly published research notes: Zacks Small-Cap Research on 2023-12-07, Ladenburg Thalmann & Co. on 2023-12-07, Ladenburg Thalmann & Co. on 2023-03-28, and Zacks Investment Research on 2022-09-13.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "13 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001860657.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ALLR"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1860657/000143774926010310/allr20251231_10k.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://allarity.com/analysts/"
  },
  {
   "for": "open research",
   "source": "https://allarity.com/wp-content/uploads/2023/12/Zacks_SCR_Research_12072023_ALLR_Vandermosten_Note.pdf"
  },
  {
   "for": "open research",
   "source": "https://allarity.com/wp-content/uploads/2023/12/ALLR-note-12.7.2023.pdf"
  },
  {
   "for": "open research",
   "source": "https://allarity.com/wp-content/uploads/2023/03/ALLR-note-3.28.2023-Ladenburg.pdf"
  },
  {
   "for": "open research",
   "source": "https://allarity.com/wp-content/uploads/2024/01/Zacks_SCR_Research_09132022_ALLR_Vandermosten.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/ALLR"
  }
 ],
 "title": "Allarity Therapeutics, Inc. (ALLR) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}